Biotechnology6 months ago
Onesource Specialty Pharma Limited (NSE: Onesource) Q4 FY26: Strong Revenue and Ebitda Recovery
OneSource Specialty Pharma Limited (NSE: ONESOURCE) announced strong Q4 FY26 results with revenue up 47% QoQ and EBITDA expanding more than 5x.
